omav Early Access Program Not Impacted by PBAC Decision

Professor Martin Delatycki of the Murdoch Childrens Research Institute has asked that we share the following communication with our community.

I would like to reassure the community that the recent outcome of the Pharmaceutical Benefits Advisory Committee (PBAC) recommendation not to reimburse omaveloxolone in no way affects the Omaveloxolone Early Access Program (EAP) that is underway. 

Omaveloxolone will continue to be provided free of charge by Biogen to Australian participants already registered in the EAP for as long as the person is judged by their treating healthcare professional to clinically benefit from this medicine. Supply will continue until omaveloxolone is available to those people enrolled in the EAP, through a formal funding mechanism, such as the Pharmaceutical Benefits Scheme.

I am also aware that Biogen remains committed to engaging with the PBAC to explore further options for reimbursement of omaveloxolone.

Professor Martin Delatycki 

Clinical Geneticist, Victorian Clinical Genetics Services
Co-Director, Bruce Lefroy Centre for Genetic Health Research
Murdoch Childrens Research Institute
Flemington Road Parkville, 3052
Victoria Australia

If you would like to be considered for the omaveloxolone Early Compassionate Access program, please email Varlli Scott varlli.scott@mcri.edu.au .